215-987-2019

IARC Declares All Forms of Asbestos Cause Cancer

 

A common defense employed in most mesothelioma trials is that chrysotile asbestos does not cause mesothelioma. This position is once again rebuffed by the IARC.

The International Agency for Research on Cancer calls for end to use of all forms of asbestos

Kathleen Ruff, RightOnCanada.ca

In a Joint Statement, released on February 19, 2013, the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) state that all forms of asbestos are carcinogenic to humans and that the most efficient way to eliminate asbestos-related diseases is to stop the use of all forms of asbestos.

In a letter of December 13, 2012, scientists and public health defenders around the world expressed concerns that IARC (an agency of the WHO) was participating in a sham scientific conference in Kiev, organized by asbestos promoters to try to prevent chrysotile asbestos being put on the Rotterdam Convention's list of hazardous substances at the upcoming May 2013 Conference of the Parties to the Rotterdam Convention.

The scientists and public health defenders also expressed their concern that, in its presentation at the Kiev conference, IARC used outdated and inaccurate information regarding chrysotile asbestos that minimized the harm it causes to health. They also expressed concern that IARC is collaborating in a study on chrysotile asbestos with a discredited institute in Russia and with discredited scientists, who promote use of chrysotile asbestos and deny that it is hazardous to health.

This Joint Statement from the WHO and IARC exposes the deadly deception of the campaign being waged by the asbestos industry to prevent chrysotile asbestos from being put on the Rotterdam Convention's list of hazardous substances as the dangerous, as the Convention's expert scientific committee has repeatedly recommended.

The other issues raised by the scientists and public health defenders have not yet been addressed by IARC and continue to be of concern.

Joint WHO/IARC Statement

In response to allegations in the recent Lancet article, IARC in the dock over ties with asbestos industry (The Lancet, doi:10.1016/S0140-6736(13)60152-X), WHO (World Health Organization) and IARC (International Agency for Reserach on Cancer) state the following:

All forms of asbestos are carcinogenic to humans (IARC Monographs Volume 100C) and stopping the use of all forms of asbestos is the most efficient way to eliminate asbestos-related diseases (WHO Fact Sheet No 343).

The study on cancer in chrysotile workers in Asbest, Russian Federation, for which IARC is providing its epidemiological expertise, will supply important scientific information to better quantify the risk of cancers already known to be related to chrysotile as well as additional cancers suspected to be related to chrysotile, the asbestos fibre is the most commonly produced.

WHO and IARC take conflict of interest seriously and use a rigorous process to protect our research and development of norms, standards and guidelines from undue influence.

IARC confirms the completeness and accuracy of all data and statements of scientific results published in the British Journal of Cancer (Estimating the asbestos-related lung cancer burden from mesothelioma mortality, doi:10.1038/bjc.2011.563) and presented at a conference in Kiev.

IARC, as WHO's cancer research agency, remains committed to providing the most reliable, independent scientific evidence on which public health decisions can be based.

 

Protein Test Developed By NYU Shows Promise For Early Detection of Mesothelioma

asbestos has been found in buildings throughout new york cityOn April 4, 2011 researchers at NYU Langone Medical Center presented a study at the American Association for Cancer Research 102nd Annual Meeting held in Orlando, Florida, which detailed their findings on a protein test that may be used to detect early-stage, asbestos-related pulmonary disease.  According to researchers, the test can accurately identify proteins secreted from cancerous tumors caused by asbestos exposure.

Dr Harvey Pass, director of the Division of Thoracic Surgery and Thoracic Oncology at NYU Langone Medical Center and the NYU Cancer Institute, spoke about a novel biomarker test that is believed to be the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. In a blinded test the proteomic assay could detect 15 of 19 cases of malignant pleural mesothelioma that were in stage 1 or stage 2, making the test about 80 percent sensitive, a measure of how accurately a test can identify disease. In addition, the specificity of the test was 100 percent.

“The goal of a new diagnostic test is to find the cancer early enough to effectively treat it”, according to Harvey I. Pass, MD.

To read the full article visit:   http://communications.med.nyu.edu/news/2011/new-test-detects-early-stage-asbestos-related-pulmonary-cancer

More Reason to Hope for New Jersey & Pennsylvania Mesolthelioma Patients

The news for mesothelioma treatment continues reason for hope. Drug researchers from China and the United States are working together on the KDR/Kit Inhibitor, which will work to end the new growth of cancerous cells in patients.

The two companies, China-based Simcere Pharmaceutical Group and OSI Pharmaceuticals in the U.S., are basing the project in China. OSI specializes in the discovery and development of innovative molecular targeted therapies. The drug, called OSI-930 for now, has shown positive results in treating small and non-small cell lung cancer, colorectal, gastric and other cancers. Its effectiveness in treating these cancers has the teams working on its treatment of mesothelioma as well.

ONCONASE May Provide Significant Efficacy in Patients with Malignant Mesothelioma

As reported in http://www.medicalnewstoday.com/articles/124975.php

 

Alfacell Corporation (Nasdaq: ACEL) announced that a paper published in Cell Cycle (2008; Vol. 7, Issue 20) reports that ONCONASE (ranpirnase) targets small interfering RNA (siRNA), likely within the RNA-induced silencing complex (RISC) of the RNA interference (RNAi) mechanism.

The paper is the result of research conducted by collaborators at the Brander Cancer Research Institute and Department of Pathology at New York Medical College and Alfacell. The study demonstrated that silencing the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene (an abundant and ubiquitously expressed housekeeping gene) in human lung adenocarcinoma A549 cells by siRNA was effectively prevented by ONCONASE. While transfection of cells with GAPDH siRNA reduced expression of this protein by nearly 70 percent, the expression was restored in the cells exposed to ONCONASE for 48 or 72 hours. The data thus provide evidence that one of the targets of ONCONASE (ranpirnase) is siRNA.

"This data provide further evidence of the impact of ONCONASE on the RNAi mechanism," said Kuslima Shogen, Alfacell’s chief executive officer. "Furthermore, the data may provide the explanation for the preferential effectiveness of ONCONASE toward tumor cells as well as its ability to sensitize cells to other antitumor agents. As seen in our Phase III clinical trial results, ONCONASE has demonstrated significant efficacy in patients with malignant mesothelioma that failed prior chemotherapy."
 

Last updated by at .